Article Text

PDF
Low folate levels may protect against colorectal cancer
  1. B Van Guelpen1,
  2. J Hultdin2,
  3. I Johansson3,
  4. G Hallmans4,
  5. R Stenling1,
  6. E Riboli5,
  7. A Winkvist6,
  8. R Palmqvist1
  1. 1Department of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden
  2. 2Department of Medical Biosciences, Clinical Chemistry, Umeå University, Umeå, Sweden
  3. 3Department of Odontology, Cardiology, Umeå University, Umeå, Sweden
  4. 4Department of Public Health and Clinical Medicine, Nutrition Research, Umeå University, Umeå, Sweden
  5. 5Department of Epidemiology, Imperial College London, London, UK
  6. 6Department of Clinical Nutrition, The Sahlgrenska Academy, Göteborg University, Gothenburg, Sweden
  1. Correspondence to:
    MsB Van Guelpen
    Department of Medical Biosciences, Pathology, Building 6M, 2nd Floor, Umeå University, SE-901 85 Umeå, Sweden; bethany.van.guelpen{at}medbio.umu.se

Abstract

Background and aims: Dietary folate is believed to protect against colorectal cancer (CRC). However, few studies have addressed the role of circulating levels of folate. The aim of this study was to relate prediagnostic plasma folate and homocysteine concentrations and the methylenetetrahydrofolate reductase (MTHFR) 677C>T and 1298A>C polymorphisms to the risk of developing CRC.

Subjects: Subjects were 226 cases and 437 matched referents from the population based Northern Sweden Health and Disease Cohort.

Results: We observed a bell-shaped association between plasma folate concentrations and CRC risk; multivariate odds ratio for middle versus lowest quintile 2.00 (95% confidence interval (CI) 1.13–3.56). In subjects with follow up times greater than the median of 4.2 years however, plasma folate concentrations were strongly positively related to CRC risk; multivariate odds ratio for highest versus lowest quintile 3.87 (95% CI 1.52–9.87; p trend = 0.007). Homocysteine was not associated with CRC risk. Multivariate odds ratios for the MTHFR polymorphisms were, for 677 TT versus CC, 0.41 (95% CI 0.19–0.85; p trend = 0.062), and for 1298 CC versus AA, 1.62 (95% CI 0.94–2.81; p trend = 0.028). Interaction analysis suggested that the result for 1298A>C may have been largely due to linkage disequilibrium with 677C>T. The reduced CRC risk in 677 TT homozygotes was independent of plasma folate status.

Conclusions: Our findings suggest a decreased CRC risk in subjects with low folate status. This possibility of a detrimental component to the role of folate in carcinogenesis could have implications in the ongoing debate in Europe concerning mandatory folate fortification of foods.

  • CRC, colorectal cancer
  • MTHFR, methylenetetrahydrofolate reductase
  • MONICA, Northern Sweden WHO Monitoring of Trends and Cardiovascular Disease Study
  • VIP, Västerbotten Intervention Project
  • MSP, Mammography Screening Project
  • OR, odds ratio
  • BMI, body mass index
  • colorectal neoplasm
  • folate
  • homocysteine
  • methylenetetrahydrofolate reductase
  • risk factors

Statistics from Altmetric.com

Footnotes

  • Published online first 26 April 2006

  • Conflict of interest: None declared.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles